把三张表、经营指标、SEC / 巨潮 / 港交所原始财报、业绩材料和电话会放到同一条可核验时间线上。 披露事实、结构化补位值与派生指标分开标注，缺失逐字稿不会用摘要或模型生成内容补齐。
单季、累计、年度和资产负债表时点分开保存；每个数值都保留单位、申报日、表单、XBRL 概念或原始中文字段。
美股链接 SEC 法定申报和发行人 IR，A 股链接巨潮原始 PDF，港股链接港交所披露易原始年报与中报。分部、订单、产能和客户集中度只在有可核验披露时展示。
官方电话会入口与已授权逐字稿分开。没有合法取得的全文时只显示材料可用性，不生成或拼接虚假的逐字稿。
三张表会执行资产负债、毛利润、税前利润等勾稽检查；超出容差的记录保留原值并标记警告， 不会为了让公式“对上”而修改公司披露。
| 2026-06-30 |
| 3/3 |
| $0 |
| -$24.84M |
| -$28.56M |
| — |
| -4917.5% |
| 78 |
| 尚无授权文本 |
| IONS IONIS PHARMACEUTICALS INC | 2026-06-30 | 3/3 | $267.95M | -$114.65M | -$265.13M | 99.0% | -38.2% | 120 | 尚无授权文本 |
| MDGL MADRIGAL PHARMACEUTICALS, INC. | 2026-06-30 | 3/3 | $364.25M | -$57.94M | -$152.21M | — | -15.5% | 87 | 尚无授权文本 |
| PHAT Phathom Pharmaceuticals, Inc. | 2026-06-30 | 3/3 | $74.27M | -$17.58M | -$17.68M | 79.7% | -5.3% | 113 | 尚无授权文本 |
| REGN REGENERON PHARMACEUTICALS, INC. | 2026-06-30 | 3/3 | $4.29B | $1.3B | — | — | 30.1% | 82 | 尚无授权文本 |
| TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | 2026-06-30 | 3/3 | $4.14B | -$576M | — | 52.0% | -5.6% | 84 | 尚无授权文本 |
| WST WEST PHARMACEUTICAL SERVICES INC | 2026-06-30 | 3/3 | $872.3M | $154M | $128M | 37.7% | 20.5% | 77 | 尚无授权文本 |
| PMCB PharmaCyte Biotech, Inc. | 2026-04-30 | 3/3 | $0 | -$19.42M | — | — | — | 70 | 尚无授权文本 |
| ABOS Acumen Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$20.74M | — | — | — | 72 | 尚无授权文本 |
| ABUS Arbutus Biopharma Corp | 2026-03-31 | 3/3 | $179.13M | $169.7M | — | — | 94.3% | 139 | 尚无授权文本 |
| ABVC ABVC BIOPHARMA, INC. | 2026-03-31 | 3/3 | — | -$1.56M | — | — | — | 99 | 尚无授权文本 |
| ACAD ACADIA PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $268.06M | $3.64M | $28.77M | 90.8% | -1.7% | 83 | 尚无授权文本 |
| ACXP Acurx Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$1.68M | — | — | — | 56 | 尚无授权文本 |
| ADIL ADIAL PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | — | -$2.02M | — | — | — | 144 | 尚无授权文本 |
| AEON AEON Biopharma, Inc. | 2026-03-31 | 3/3 | — | -$11.79M | — | — | — | 104 | 尚无授权文本 |
| AMLX Amylyx Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$41.28M | — | — | — | 68 | 尚无授权文本 |
| AMPH Amphastar Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $171.17M | $6.42M | $38.33M | 41.1% | 8.0% | 81 | 尚无授权文本 |
| AMRX Amneal Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $722.52M | $62.26M | -$34.92M | 44.3% | 19.6% | 87 | 尚无授权文本 |
| ANIP ANI PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $237.46M | $29.49M | $52.3M | — | 16.4% | 115 | 尚无授权文本 |
| APUS Apimeds Pharmaceuticals US, Inc. | 2026-03-31 | 3/3 | — | -$35.06M | -$2.08M | — | — | 24 | 尚无授权文本 |
| ARMP Armata Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$115.35M | -$5.85M | — | — | 97 | 尚无授权文本 |
| ARWR ARROWHEAD PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $73.74M | -$132.73M | $93.21M | — | -191.6% | 86 | 尚无授权文本 |
| ASBP Aspire Biopharma Holdings, Inc. | 2026-03-31 | 3/3 | $28,353 | -$3.22M | — | 20.3% | -5806.0% | 71 | 尚无授权文本 |
| ATNM Actinium Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$5.52M | -$5.87M | — | — | 46 | 尚无授权文本 |
| ATYR aTYR PHARMA INC | 2026-03-31 | 3/3 | — | -$10.79M | -$12.66M | — | — | 83 | 尚无授权文本 |
| AUPH Aurinia Pharmaceuticals Inc. | 2026-03-31 | 3/3 | $77.71M | $34.36M | — | 91.6% | 53.3% | 91 | 尚无授权文本 |
| AVBP ArriVent BioPharma, Inc. | 2026-03-31 | 3/3 | — | -$43.32M | — | — | — | 36 | 尚无授权文本 |
| AVIR Atea Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$45.44M | — | — | — | 63 | 尚无授权文本 |
| AVLN Avalyn Pharma Inc. | 2026-03-31 | 3/3 | — | -$26.87M | -$30.21M | — | — | 5 | 尚无授权文本 |
| AYTU AYTU BIOPHARMA, INC | 2026-03-31 | 3/3 | $12.41M | -$5.62M | -$1.14M | 61.2% | -32.7% | 132 | 尚无授权文本 |
| BBIO BridgeBio Pharma, Inc. | 2026-03-31 | 3/3 | $194.52M | -$166.56M | -$197.35M | 94.9% | -54.5% | 109 | 尚无授权文本 |
| BCRX BIOCRYST PHARMACEUTICALS INC | 2026-03-31 | 3/3 | — | -$721.81M | — | — | — | 132 | 尚无授权文本 |
| BMRN BIOMARIN PHARMACEUTICAL INC | 2026-03-31 | 3/3 | $766.21M | $105.53M | $199.73M | 74.6% | 16.9% | 91 | 尚无授权文本 |
| BNTC Benitec Biopharma Inc. | 2026-03-31 | 3/3 | $0 | -$11.94M | -$11.61M | — | — | 97 | 尚无授权文本 |
| CNSP CNS Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$4.94M | -$4.65M | — | — | 108 | 尚无授权文本 |
| CNTB Connect Biopharma Holdings Ltd | 2026-03-31 | 3/3 | $169,000 | -$19.4M | -$16.01M | — | -11601.8% | 75 | 尚无授权文本 |
| COCP Cocrystal Pharma, Inc. | 2026-03-31 | 3/3 | $225,000 | -$2.3M | — | — | -1047.1% | 118 | 尚无授权文本 |
| COLL COLLEGIUM PHARMACEUTICAL, INC | 2026-03-31 | 3/3 | $193.52M | $14.5M | $56.84M | 60.6% | 16.0% | 94 | 尚无授权文本 |
| CPHI CHINA PHARMA HOLDINGS, INC. | 2026-03-31 | 3/3 | $983,536 | -$1.14M | — | 29.0% | -113.6% | 54 | 尚无授权文本 |
| CPIX CUMBERLAND PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $9.13M | -$3.29M | $387,025 | 78.8% | -34.3% | 98 | 尚无授权文本 |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | 2026-03-31 | 3/3 | — | -$22.97M | -$25.58M | — | — | 118 | 尚无授权文本 |
| CRNX Crinetics Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $10.73M | -$127.85M | -$125.52M | 98.1% | -1307.8% | 122 | 尚无授权文本 |
| CRVS Corvus Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$13.69M | -$10.47M | — | — | 87 | 尚无授权文本 |
| CTXR Citius Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $1.67M | -$28.11M | — | 80.3% | -1931.0% | 137 | 尚无授权文本 |
| CUE Cue Biopharma, Inc. | 2026-03-31 | 3/3 | $5.69M | -$5.18M | -$11.06M | — | -94.1% | 76 | 尚无授权文本 |
| CURX Curanex Pharmaceuticals Inc | 2026-03-31 | 3/3 | — | -$3.15M | — | — | — | 14 | 尚无授权文本 |
| ELDN Eledon Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$39.03M | — | — | — | 84 | 尚无授权文本 |
| ELOX Eloxx Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$3.75M | — | — | — | 81 | 尚无授权文本 |
| ENTA ENANTA PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $17.16M | -$13.09M | -$19.01M | — | -69.1% | 76 | 尚无授权文本 |
| ESLA Estrella Immunopharma, Inc. | 2026-03-31 | 3/3 | — | -$2.29M | — | — | — | 77 | 尚无授权文本 |
| ETON Eton Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $24.27M | $1.55M | $7.33M | 60.7% | 9.9% | 137 | 尚无授权文本 |
| FENC FENNEC PHARMACEUTICALS INC. | 2026-03-31 | 3/3 | $15.11M | $201,000 | — | — | -0.8% | 80 | 尚无授权文本 |
| GRDN Guardian Pharmacy Services, Inc. | 2026-03-31 | 3/3 | $336.6M | $13.3M | — | 22.7% | 5.3% | 29 | 尚无授权文本 |
| GTBP GT Biopharma, Inc. | 2026-03-31 | 3/3 | — | -$2.83M | — | — | — | 90 | 尚无授权文本 |
| IGC IGC Pharma, Inc. | 2026-03-31 | 3/3 | $317,000 | -$2.4M | -$1.22M | 17.4% | -775.4% | 65 | 尚无授权文本 |
| IMMX Immix Biopharma, Inc. | 2026-03-31 | 3/3 | — | -$10.09M | -$9.86M | — | — | 49 | 尚无授权文本 |
| INDV Indivior Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $317M | $89M | -$29M | 87.4% | 43.2% | 371 | 尚无授权文本 |
| INM InMed Pharmaceuticals Inc. | 2026-03-31 | 3/3 | — | -$2.97M | — | — | — | 188 | 尚无授权文本 |
| INO INOVIO PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $0 | -$19.68M | -$21.59M | — | — | 76 | 尚无授权文本 |
| IRWD IRONWOOD PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $106.51M | $40.77M | — | — | 68.1% | 87 | 尚无授权文本 |
| JAZZ Jazz Pharmaceuticals plc | 2026-03-31 | 3/3 | $1.07B | $293.1M | $388.5M | — | 31.5% | 100 | 尚无授权文本 |
| KAPA Kairos Pharma, LTD. | 2026-03-31 | 3/3 | — | -$1.65M | — | — | — | 36 | 尚无授权文本 |
| KNSA Kiniksa Pharmaceuticals International, plc | 2026-03-31 | 3/3 | $214.27M | $22.59M | $50.04M | 90.3% | 13.7% | 80 | 尚无授权文本 |
| KPRX KIORA PHARMACEUTICALS INC | 2026-03-31 | 3/3 | — | -$2.42M | -$3.17M | — | — | 104 | 尚无授权文本 |
| KPTI Karyopharm Therapeutics Inc. | 2026-03-31 | 3/3 | $35.07M | -$22.39M | — | — | -76.3% | 105 | 尚无授权文本 |
| LBRX LB PHARMACEUTICALS INC | 2026-03-31 | 3/3 | — | -$19.05M | -$23.32M | — | — | 16 | 尚无授权文本 |
| LGND LIGAND PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $51.72M | -$13.35M | $48.46M | — | 33.6% | 110 | 尚无授权文本 |
| LIMN Liminatus Pharma, Inc. | 2026-03-31 | 3/3 | — | -$1.12M | — | — | — | 25 | 尚无授权文本 |
| LTRN Lantern Pharma Inc. | 2026-03-31 | 3/3 | — | -$3.33M | — | — | — | 71 | 尚无授权文本 |
| LXRX LEXICON PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $21.1M | -$1.04M | — | 99.5% | -4.7% | 101 | 尚无授权文本 |
| LYEL Lyell Immunopharma, Inc. | 2026-03-31 | 3/3 | $2,000 | -$24.15M | -$38.6M | — | -2213050.0% | 74 | 尚无授权文本 |
| MDCX Medicus Pharma Ltd. | 2026-03-31 | 3/3 | — | -$9.04M | — | — | — | 40 | 尚无授权文本 |
| MIRA MIRA PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | — | -$1.15M | — | — | — | 80 | 尚无授权文本 |
| MIRM Mirum Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $159.88M | -$790.16M | -$229.43M | — | -493.8% | 96 | 尚无授权文本 |
| MIST Milestone Pharmaceuticals Inc. | 2026-03-31 | 3/3 | $238,000 | -$26.07M | -$16.1M | 94.1% | -9942.4% | 82 | 尚无授权文本 |
| MREO Mereo BioPharma Group plc | 2026-03-31 | 3/3 | — | -$6.72M | -$4.31M | — | — | 114 | 尚无授权文本 |
| MTNB Matinas BioPharma Holdings, Inc. | 2026-03-31 | 3/3 | — | -$1.92M | — | — | — | 107 | 尚无授权文本 |
| NAMS NewAmsterdam Pharma Co N.V. | 2026-03-31 | 3/3 | $3.04M | -$48.44M | — | — | -1921.7% | 83 | 尚无授权文本 |
| NRXP NRX Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $1.07M | -$1.43M | — | 40.9% | -444.0% | 134 | 尚无授权文本 |
| NVCT Nuvectis Pharma, Inc. | 2026-03-31 | 3/3 | — | -$6.05M | — | — | — | 53 | 尚无授权文本 |
| OLMA Olema Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$53.09M | — | — | — | 84 | 尚无授权文本 |
| ORIC Oric Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$35.77M | -$32.44M | — | — | 84 | 尚无授权文本 |
| ORMP ORAMED PHARMACEUTICALS INC. | 2026-03-31 | 3/3 | — | $38.31M | -$2.92M | — | — | 104 | 尚无授权文本 |
| PCSA Processa Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$3.38M | — | — | — | 116 | 尚无授权文本 |
| PHIO Phio Pharmaceuticals Corp. | 2026-03-31 | 3/3 | — | -$4M | -$4M | — | — | 114 | 尚无授权文本 |
| PMVP PMV Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$18.04M | -$19.68M | — | — | 65 | 尚无授权文本 |
| PPCB Propanc Biopharma, Inc. | 2026-03-31 | 3/3 | — | -$6.36M | -$4.09M | — | — | 93 | 尚无授权文本 |
| QNRX Quoin Pharmaceuticals, Ltd. | 2026-03-31 | 3/3 | — | -$5M | — | — | — | 118 | 尚无授权文本 |
| RARE Ultragenyx Pharmaceutical Inc. | 2026-03-31 | 3/3 | $136M | -$185M | -$198M | — | -124.3% | 119 | 尚无授权文本 |
| RCKT ROCKET PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $0 | -$47.59M | -$45.49M | — | — | 97 | 尚无授权文本 |
| RIGL RIGEL PHARMACEUTICALS INC | 2026-03-31 | 3/3 | $58.82M | $8.65M | — | 92.2% | 20.2% | 94 | 尚无授权文本 |
| RPRX Royalty Pharma plc | 2026-03-31 | 3/3 | $630.58M | $294.69M | — | — | 89.3% | 99 | 尚无授权文本 |
| RXRX RECURSION PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $6.47M | -$117.5M | -$81.36M | -93.0% | -1985.6% | 103 | 尚无授权文本 |
| RYTM RHYTHM PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $60.11M | -$55.64M | — | 88.1% | -87.1% | 98 | 尚无授权文本 |
| SBFM Sunshine Biopharma Inc. | 2026-03-31 | 3/3 | $8.09M | -$1.24M | -$2.08M | 27.0% | -17.3% | 87 | 尚无授权文本 |
| SGP SpyGlass Pharma, Inc. | 2026-03-31 | 3/3 | — | -$13.82M | -$14.22M | — | — | 7 | 尚无授权文本 |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. | 2026-03-31 | 3/3 | — | -$2.15M | — | — | — | 109 | 尚无授权文本 |
| SILO Silo Pharma, Inc. | 2026-03-31 | 3/3 | $18,026 | -$1.65M | — | -14.8% | -8846.4% | 87 | 尚无授权文本 |
| SNDX Syndax Pharmaceuticals Inc | 2026-03-31 | 3/3 | $64.86M | -$42.67M | — | — | -52.7% | 91 | 尚无授权文本 |
| SNOA Sonoma Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $19.53M | -$3.18M | -$4.13M | 38.0% | -12.6% | 89 | 尚无授权文本 |
| SPRY ARS Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $22.68M | -$60.62M | -$44.95M | — | -265.2% | 87 | 尚无授权文本 |
| STRO SUTRO BIOPHARMA, INC. | 2026-03-31 | 3/3 | $14.52M | -$38.48M | — | — | -204.2% | 96 | 尚无授权文本 |
| SUPN SUPERNUS PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $207.71M | -$2.29M | $66.52M | 88.7% | -4.0% | 142 | 尚无授权文本 |
| SXTC China SXT Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$6.21M | — | — | — | 46 | 尚无授权文本 |
| SXTP 60 DEGREES PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $162,092 | -$2.09M | -$2.77M | 47.1% | -1292.5% | 54 | 尚无授权文本 |
| TARS Tarsus Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | $162.05M | -$6.97M | -$30.47M | 94.2% | -3.8% | 89 | 尚无授权文本 |
| TBPH Theravance Biopharma, Inc. | 2026-03-31 | 3/3 | $17.7M | -$4.93M | — | — | -53.6% | 102 | 尚无授权文本 |
| TELO Telomir Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$990,947 | — | — | — | 68 | 尚无授权文本 |
| TNXP Tonix Pharmaceuticals Holding Corp. | 2026-03-31 | 3/3 | $6.88M | -$40.19M | -$44.01M | 77.1% | -603.9% | 393 | 尚无授权文本 |
| TRAW Traws Pharma, Inc. | 2026-03-31 | 3/3 | — | -$7.11M | — | — | — | 135 | 尚无授权文本 |
| URGN UroGen Pharma Ltd. | 2026-03-31 | 3/3 | $50.96M | -$23.57M | -$45.37M | 91.9% | -39.8% | 87 | 尚无授权文本 |
| VNDA Vanda Pharmaceuticals Inc. | 2026-03-31 | 3/3 | $51.72M | -$48.57M | -$50.44M | — | -97.1% | 99 | 尚无授权文本 |
| VOR Vor Biopharma Inc. | 2026-03-31 | 3/3 | — | -$219.59M | -$38.29M | — | — | 70 | 尚无授权文本 |
| VRCA Verrica Pharmaceuticals Inc. | 2026-03-31 | 3/3 | $5.02M | -$9.68M | — | — | -193.4% | 103 | 尚无授权文本 |
| VRTX VERTEX PHARMACEUTICALS INC / MA | 2026-03-31 | 3/3 | $2.99B | $1.03B | $1.29B | 86.8% | 38.1% | 72 | 尚无授权文本 |
| XENE Xenon Pharmaceuticals Inc. | 2026-03-31 | 3/3 | — | -$102.3M | -$89.03M | — | — | 90 | 尚无授权文本 |
| XERS Xeris Biopharma Holdings, Inc. | 2026-03-31 | 3/3 | $83.13M | $2.23M | — | — | 9.5% | 72 | 尚无授权文本 |
| XFOR X4 Pharmaceuticals, Inc | 2026-03-31 | 3/3 | $2.71M | -$20.24M | — | 77.9% | -749.9% | 123 | 尚无授权文本 |
| ZBIO Zenas BioPharma, Inc. | 2026-03-31 | 3/3 | — | -$80.99M | -$75.2M | — | — | 25 | 尚无授权文本 |
| ZNTL Zentalis Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$35.35M | -$32.99M | — | — | 108 | 尚无授权文本 |
| ASND Ascendis Pharma A/S | 2025-12-31 | 2/3 | — | -$228.03M | — | — | — | 262 | 尚无授权文本 |
| BDRX Biodexa Pharmaceuticals Plc | 2025-12-31 | 2/3 | — | -$6.38M | — | — | — | 141 | 尚无授权文本 |
| CANF Can-Fite BioPharma Ltd. | 2025-12-31 | 3/3 | $405,000 | -$9.83M | -$8.95M | — | -2456.8% | 221 | 尚无授权文本 |
| EPRX EUPRAXIA PHARMACEUTICALS INC. | 2025-12-31 | 3/3 | $0 | -$38.58M | — | — | — | 84 | 尚无授权文本 |
| GLMD Galmed Pharmaceuticals Ltd. | 2025-12-31 | 3/3 | — | -$10.31M | — | — | — | 125 | 尚无授权文本 |
| IPHA Innate Pharma SA | 2025-12-31 | 2/3 | — | -$49.18M | — | — | — | 253 | 尚无授权文本 |
| NGEN NERVGEN PHARMA CORP. | 2025-12-31 | 2/3 | — | -$44.12M | — | — | — | 12 | 尚无授权文本 |
| NSRX Nasus Pharma Ltd | 2025-12-31 | 3/3 | $1.24B | -$5.86M | -$4.93M | — | -0.4% | 21 | 尚无授权文本 |
| PHAR Pharming Group N.V. | 2025-12-31 | 2/3 | — | $2.54M | — | — | — | 115 | 尚无授权文本 |
| PHVS Pharvaris N.V. | 2025-12-31 | 2/3 | — | -$175.7M | — | — | — | 76 | 尚无授权文本 |
| QNTM Quantum Biopharma Ltd. | 2025-12-31 | 2/3 | — | — | — | — | — | 271 | 尚无授权文本 |
| TLX Telix Pharmaceuticals Ltd | 2025-12-31 | 2/3 | — | -$7.13M | — | — | — | 57 | 尚无授权文本 |
| UPC Universe Pharmaceuticals INC | 2025-09-30 | 3/3 | $17.86B | -$3.67B | -$5.32B | 35.3% | -16.3% | 52 | 尚无授权文本 |
| RADX Radiopharm Theranostics Ltd | 2025-06-30 | 2/3 | — | -$38.34M | — | — | — | 75 | 尚无授权文本 |
| RDHL RedHill Biopharma Ltd. | 2025-06-30 | 2/3 | — | -$4.13M | — | — | — | 305 | 尚无授权文本 |
| OKYO OKYO Pharma Ltd | 2025-03-31 | 2/3 | — | -$4.71M | — | — | — | 154 | 尚无授权文本 |
| TAK TAKEDA PHARMACEUTICAL CO LTD | 2025-03-31 | 2/3 | — | $108.14B | — | — | — | 272 | 尚无授权文本 |
| AAPG ASCENTAGE PHARMA GROUP INTERNATIONAL | 2024-12-31 | 2/3 | — | -$405.68M | — | — | — | 69 | 尚无授权文本 |
| XTLB XTL BIOPHARMACEUTICALS LTD | 2024-12-31 | 2/3 | — | -$1.03M | — | — | — | 75 | 尚无授权文本 |
| VCRE Vicore Pharma Holding AB | — | 0/3 | — | — | — | — | — | 1 | 尚无授权文本 |